Trials / Recruiting
RecruitingNCT07063212
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
A Phase II Study of Sacituzumab Govitecan in Combination With Cetuximab in Patients With Recurrent Metastatic HNSCC That Has Progressed After First-Line Therapy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
Conditions
- Squamous Cell Carcinoma of Head and Neck
- Sinus Cancer
- Nasal Cavity Cancer
- Oral Cavity Cancer
- Oropharynx Cancer
- Hypopharynx Cancer
- Larynx Cancer
- Oral Squamous Cell Carcinoma
- Oropharynx Squamous Cell Carcinoma
- Hypopharynx Squamous Cell Carcinoma
- Larynx Squamous Cell Carcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Govitecan | Sacituzumab govitecan (SG; Trodelvy®) is a trophoblast cell-surface antigen 2 (Trop-2)- directed antibody-drug conjugate |
| DRUG | Cetuximab | Cetuximab (also known as ERBITUX®) is an epidermal growth factor receptor (EGFR) antagonist |
Timeline
- Start date
- 2025-07-02
- Primary completion
- 2028-01-02
- Completion
- 2028-01-02
- First posted
- 2025-07-14
- Last updated
- 2026-02-19
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07063212. Inclusion in this directory is not an endorsement.